Sponsors (36)
Official title: Prohibit certain uses of xylazine, and for other purposes.
Introduced February 12, 2025 by Catherine Marie Cortez Masto · Last progress February 12, 2025
The bill tightens federal control and enforcement for xylazine and creates reporting mechanisms to inform policy — improving enforcement consistency and public-health data while risking increased criminalization, higher compliance costs, access challenges for legitimate medical/veterinary uses, and short-term enforcement complexities.
Law enforcement and prosecutors gain clearer, expanded statutory authority to identify, schedule, seize, and prosecute xylazine-related activity, and judges receive clearer sentencing guidance, producing more consistent federal enforcement across districts.
Scheduling xylazine combined with mandated HHS/DOJ reporting will likely reduce street availability and accidental exposures and give public-health agencies better data to target harm-reduction and treatment responses.
The bill creates transitional protections (delays/exemptions, grandfathering, and explicit ultimate-user carve-outs) plus requirements for agencies to expedite manufacturer submissions, which helps preserve veterinary and medical access and avoids immediate supply disruption.
People who use or possess xylazine-containing substances face greater criminal risk — including broader arrests and harsher, more uniform penalties — which will disproportionately affect low-income people and may increase incarceration.
Tighter controls and scheduling may restrict legitimate medical and veterinary access to xylazine formulations, complicating procurement and care for animals and some patients.
The Act will raise regulatory, compliance, and administrative costs for manufacturers, distributors, pharmacies, clinics, and registrants (and potentially increase taxpayer costs via larger prison populations), imposing a sustained economic burden on the health supply chain and government budgets.
Based on analysis of 7 sections of legislative text.
Adds xylazine (and salts/isomers) to Schedule III, changes definitions and recordkeeping, delays some compliance duties, requires sentencing review, and mandates reports to Congress.
Makes xylazine — including its salts and isomers — a Schedule III controlled substance and adds related definitions and implementation rules. The bill phases in some compliance requirements (short delays for practitioners and manufacturers), directs DEA and FDA to expedite certain submissions, requires the U.S. Sentencing Commission to review federal drug sentencing guidance for xylazine offenses, and mandates several reports to Congress on xylazine prevalence and risks. The law changes criminal and regulatory treatment of xylazine-containing products, provides limited transitional relief for manufacturers and practitioners, and directs law enforcement, public-health, and regulatory agencies to study, report, and update guidance and labeling related to xylazine misuse and trafficking.